IVI in the Media

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

IVI and Sweden Partner to Discover, Develop, and Deliver Vaccines for the Developing World

Author
Margaret
Date
2014-10-17 00:00
Views
3227

IVI and Sweden Partner to

Discover, Develop, and Deliver Vaccines

for the Developing World

 

SEOUL, KOREA – The International Vaccine Institute (IVI), a Seoul-based non-profit international organization, announced today that it has entered into a five-year agreement on core support with the Swedish International Development Cooperation Agency (Sida).  As a representative of the Swedish government on Sweden’s Policy for Global Development, Sida has agreed to support IVI’s core activities to help fulfill the Institute’s mission to discover, develop, and deliver safe, effective, and affordable vaccines for the world’s developing nations. The Swedish contribution totals 34.5 million Swedish Krona (approximately $5 million USD) and is effective from 2015 to 2019.  

 

“We are extremely grateful to Sida and the Swedish government for their commitment to IVI,” said Mr. John Morahan, IVI’s Acting Director General and Chief Financial Officer, “With previous Swedish support, IVI led the initiative to accelerate the development and introduction of the world’s first low-cost oral cholera vaccine. This vaccine was prequalified by the World Health Organization and is now being used to fight cholera around the world by agencies such as UNICEF.”

 

IVI and Sweden have had a longstanding partnership. Sweden is one of the 35 signatory countries on IVI’s Establishment Agreement and has been so since IVI’s inception in 1997. It has contributed significantly to the organization’s development and growth throughout the years. Sida has financially supported IVI since 2002, and Sweden continues to be a member of IVI’s Board of Trustees. The Institute also hosted Her Majesty Queen Silvia of Sweden during her state visit to South Korea in May 2012.

 

In addition to development of the oral cholera vaccine, with Swedish support, IVI established a state-of-the-art vaccine research and training laboratory in Kolkata, India; organized an annual vaccinology course for developing country health professionals and scientists that has become the flagship vaccinology course in the Asia-Pacific region; established a policy and economic research unit to help government officials and decision makers make informed policy decisions on vaccine introduction; and successfully expanded its field research programs from Asia to Africa.

 

"We are proud to be one of the contributors to IVI", said Mrs. Anna Maria Oltorp, Head of Unit for Research Cooperation, Sida. "The Swedish funds are provided as core support, which we consider to be a strategic choice in order to allow IVI to further develop its scientific agenda. If IVI has to rely on project funding alone there is a clear risk that the innovative thinking will be hampered."

 

“Sweden is among our most important stakeholders, which also includes our host country of South Korea and the Bill & Melinda Gates Foundation,” said Mr. Morahan “With continued support from Sweden, IVI will continue to make a greater impact by improving the health of the world’s most vulnerable populations through vaccines and vaccination. We look forward to continuing the partnership with Sida in the years to come.”

 

 

 

About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.

 

 

 

 

Media Contact:

 

Tae Kyung Byun

Public Awareness/Advocacy Officer, IVI

Phone: +82-2-872-2801 (Ext. 159)     

Mobile: +82-11-9773-6071

Email: tkbyun@ivi.int

 

 

 

DONATE